What is Complement Therapeutics?
Complement Therapeutics is a biotechnology firm dedicated to pioneering new therapies by harnessing insights from the Complement System. Their research focuses on developing advanced treatments, including AAV gene therapies and protein-based interventions, for debilitating conditions like age-related macular degeneration and other diseases driven by complement pathway dysregulation. With a strong foundation in world-leading expertise and proprietary research, the company's lead asset, CTx001, is currently in pre-clinical development for Geographic Atrophy, a condition with a significant unmet medical need. Complement Therapeutics aims to revolutionize patient care for complement-mediated diseases through its cutting-edge research and development platforms.
How much funding has Complement Therapeutics raised?
Complement Therapeutics has raised a total of $84.7M across 2 funding rounds:
Angel/Seed
$5.7M
Series A
$79M
Angel/Seed (2022): $5.7M with participation from BGV (BioGeneration Ventures and Forbion
Series A (2023): $79M led by Panakes Partners, Generate BioVentures, Forbion, Cambridge Innovation Capital, Seroba Life Sciences Management, Gimv, and Hadean Ventures
Key Investors in Complement Therapeutics
BGV (BioGeneration Ventures
BioGeneration Ventures is a venture capital firm specializing in seed investments for innovative early-stage life science companies, particularly in Europe. They act as lead investors and offer expertise and support to accelerate product development for companies addressing high unmet medical needs in the biotech sector.
Forbion
Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating the company's philosophy that investments in companies should positively impact the health and well-being of patients.
Panakes Partners
Panakès Partners is a Venture Capital investor that finances medical companies, early stage startups and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields.
What's next for Complement Therapeutics?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for Complement Therapeutics. This capital infusion is expected to accelerate the development of its lead asset, CTx001, and further advance its pipeline of innovative therapies targeting complement-related diseases. The company is well-positioned to leverage this backing to progress through clinical trials and potentially bring transformative treatments to patients. Future strategic partnerships and continued investment in research and development will likely be key to realizing the company's mission of addressing significant unmet medical needs in the biotechnology sector.
See full Complement Therapeutics company page
